Alpa Laboratories Limited (ALPA.BO)
INR 105.3
(1.4%)
INR 105.3
(1.4%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 167.76 Million INR | 32.81% |
| 2022 | 126.32 Million INR | -10.36% |
| 2021 | 140.91 Million INR | 94.45% |
| 2020 | 72.47 Million INR | 291.02% |
| 2019 | 18.53 Million INR | 83.2% |
| 2018 | 10.11 Million INR | -63.96% |
| 2017 | 28.06 Million INR | 11.38% |
| 2016 | 25.2 Million INR | -63.19% |
| 2015 | 68.46 Million INR | 589.81% |
| 2014 | -13.97 Million INR | 72.89% |
| 2013 | -51.54 Million INR | -18.01% |
| 2012 | -43.68 Million INR | -926.49% |
| 2011 | 5.28 Million INR | -41.53% |
| 2010 | 9.03 Million INR | 13.48% |
| 2009 | 7.96 Million INR | 110.39% |
| 2008 | 3.78 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 50.96 Million INR | 44.14% |
| 2023 Q4 | 35.35 Million INR | -21.59% |
| 2023 Q1 | 30.33 Million INR | -34.1% |
| 2023 Q2 | 57.89 Million INR | 90.88% |
| 2023 Q3 | 45.09 Million INR | -22.11% |
| 2023 FY | 167.76 Million INR | 32.81% |
| 2022 Q2 | 2.02 Million INR | -92.53% |
| 2022 FY | 126.32 Million INR | -10.36% |
| 2022 Q4 | 46.02 Million INR | -10.09% |
| 2022 Q3 | 51.19 Million INR | 2434.26% |
| 2022 Q1 | 27.03 Million INR | 177.42% |
| 2021 Q3 | 54.08 Million INR | -5.4% |
| 2021 Q4 | -34.91 Million INR | -164.56% |
| 2021 Q2 | 57.16 Million INR | -11.49% |
| 2021 Q1 | 64.58 Million INR | 419.36% |
| 2021 FY | 140.91 Million INR | 94.45% |
| 2020 Q2 | 3.86 Million INR | -87.97% |
| 2020 Q4 | -20.22 Million INR | -154.22% |
| 2020 Q1 | 32.12 Million INR | 238.17% |
| 2020 FY | 72.47 Million INR | 291.02% |
| 2020 Q3 | 37.29 Million INR | 864.99% |
| 2019 Q3 | 25.79 Million INR | 567.45% |
| 2019 FY | 18.53 Million INR | 83.2% |
| 2019 Q1 | 12.12 Million INR | 137.35% |
| 2019 Q2 | 3.86 Million INR | -68.12% |
| 2019 Q4 | -23.25 Million INR | -190.13% |
| 2018 Q3 | 23.77 Million INR | 1090.98% |
| 2018 Q1 | 8.96 Million INR | 0.0% |
| 2018 FY | 10.11 Million INR | -63.96% |
| 2018 Q4 | -32.45 Million INR | -236.54% |
| 2018 Q2 | 1.99 Million INR | -77.73% |
| 2017 FY | 28.06 Million INR | 11.38% |
| 2016 FY | 25.2 Million INR | -63.19% |
| 2015 FY | 68.46 Million INR | 589.81% |
| 2015 Q2 | 58.68 Million INR | 97.79% |
| 2015 Q1 | 29.66 Million INR | -16.79% |
| 2014 Q1 | -21.86 Million INR | -90.64% |
| 2014 Q2 | -12.34 Million INR | 43.53% |
| 2014 Q3 | -15.41 Million INR | -24.83% |
| 2014 Q4 | 35.65 Million INR | 331.3% |
| 2014 FY | -13.97 Million INR | 72.89% |
| 2013 FY | -51.54 Million INR | -18.01% |
| 2013 Q2 | -26.49 Million INR | -104.76% |
| 2013 Q3 | -639 Thousand INR | 97.59% |
| 2013 Q4 | -11.47 Million INR | -1695.15% |
| 2013 Q1 | -12.93 Million INR | 50.21% |
| 2012 Q3 | -18.14 Million INR | -335.14% |
| 2012 Q2 | -4.16 Million INR | -193.92% |
| 2012 Q1 | 4.43 Million INR | 417.64% |
| 2012 FY | -43.68 Million INR | -926.49% |
| 2012 Q4 | -25.98 Million INR | -43.24% |
| 2011 Q3 | 3.8 Million INR | 0.0% |
| 2011 Q4 | -1.39 Million INR | -136.69% |
| 2011 FY | 5.28 Million INR | -41.53% |
| 2010 FY | 9.03 Million INR | 13.48% |
| 2009 FY | 7.96 Million INR | 110.39% |
| 2008 FY | 3.78 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 97.276% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 99.471% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 96.437% |
| Granules India Limited | 4.05 Billion INR | 95.861% |
| Indoco Remedies Limited | 984.6 Million INR | 82.961% |
| Achyut Healthcare Limited | 5.73 Million INR | -2826.814% |
| Ajanta Pharma Limited | 8.16 Billion INR | 97.944% |
| Alkem Laboratories Limited | 17.95 Billion INR | 99.066% |
| Brooks Laboratories Limited | -195.91 Million INR | 185.63% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 89.613% |
| Bajaj HealthCare Limited | -837.93 Million INR | 120.021% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 77.766% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.699% |
| Eris Lifesciences Limited | 3.91 Billion INR | 95.72% |
| FDC Limited | 3.05 Billion INR | 94.504% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 101.117% |
| Gufic Biosciences Limited | 861.35 Million INR | 80.523% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 96.015% |
| Ipca Laboratories Limited | 5.47 Billion INR | 96.935% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 25.315% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 185.037% |
| Lasa Supergenerics Limited | -217.3 Million INR | 177.202% |
| Laurus Labs Limited | 1.6 Billion INR | 89.551% |
| Lupin Limited | 19.14 Billion INR | 99.124% |
| Mankind Pharma Limited | 19.12 Billion INR | 99.123% |
| Medicamen Biotech Limited | 109.31 Million INR | -53.476% |
| Medico Remedies Limited | 82.9 Million INR | -102.348% |
| Megasoft Limited | -127.46 Million INR | 231.615% |
| NATCO Pharma Limited | 13.88 Billion INR | 98.792% |
| Piramal Pharma Limited | 178.2 Million INR | 5.856% |
| RPG Life Sciences Limited | 876.6 Million INR | 80.862% |
| Sigachi Industries Limited | 571.8 Million INR | 70.66% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.825% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 94.413% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 33.727% |
| Unichem Laboratories Limited | -704.74 Million INR | 123.805% |
| Wanbury Limited | 559.56 Million INR | 70.019% |
| Windlas Biotech Limited | 581.87 Million INR | 71.168% |
| ZIM Laboratories Limited | 172.46 Million INR | 2.725% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 99.565% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 104.333% |
| Divi's Laboratories Limited | 16 Billion INR | 98.951% |
| Hester Biosciences Limited | 188.89 Million INR | 11.184% |
| Procter & Gamble Health Limited | 2 Billion INR | 91.653% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 62.696% |
| Bal Pharma Limited | 73.92 Million INR | -126.949% |
| Strides Pharma Science Limited | -706.14 Million INR | 123.758% |
| Venus Remedies Limited | 284.9 Million INR | 41.116% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 92.265% |
| Nectar Lifesciences Limited | 49.95 Million INR | -235.866% |
| Shilpa Medicare Limited | 318.74 Million INR | 47.367% |
| Aarti Drugs Limited | 1.71 Billion INR | 90.213% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 87.52% |
| Suven Life Sciences Limited | -1.05 Billion INR | 115.966% |
| Ind-Swift Limited | 142.31 Million INR | -17.885% |
| Valiant Laboratories Limited | 3.19 Million INR | -5149.218% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 96.964% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 102.957% |
| Themis Medicare Limited | 435.23 Million INR | 61.454% |
| Hikal Limited | 696.02 Million INR | 75.897% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 98.987% |
| Sequent Scientific Limited | -358.69 Million INR | 146.772% |
| Novartis India Limited | 851.9 Million INR | 80.307% |
| Wockhardt Limited | -4.63 Billion INR | 103.623% |
| Jubilant Pharmova Limited | 771 Million INR | 78.241% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -2265.553% |
| Neuland Laboratories Limited | 3 Billion INR | 94.409% |
| Morepen Laboratories Limited | 961.59 Million INR | 82.554% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -14.897% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 284.932% |